ALESHKIN VLADIMIR ANDRIANOVICH;GALIMZJANOV KHALIL MINGALIEVICH;AFANAS'EV STANISLAV STEPANOVICH;ALEKSANJAN IGOR' JUR'EVICH;AMERKHANOVA ADELAIDA M;CHALOV VIKTOR VLADIMIROVICH;RUBAL'SKIJ OLEG VASIL'EVICH
发明人:
Chalov Viktor Vladimirovich (RU),Чалов Виктор Владимирович (RU),Aleshkin Vladimir Andrianovich (RU),Алешкин Владимир Андрианович (RU),Galimzjanov Khalil Mingalievich (RU),Галимзянов Халил Мингалиевич,CHALOV VIKTOR VLADIMIROVICH,ALESHKIN VLADIMIR ANDRIANOVICH,GALIMZJANOV KHALIL MINGALIEVICH,Галимзянов Халил Мингалиевич (RU),AFANASEV S
申请号：
RU2008131894/15
公开号：
RU0002453320C2
申请日:
2008.08.05
申请国别(地区):
RU
年份:
2012
代理人:
摘要：
FIELD: medicine.SUBSTANCE: group of inventions refers to pharmaceutical industry and medicine and is applicable for producing and using medical immunobiological preparations containing nonpathogenic microorganisms. The compositions (versions) represent a powder containing substances containing nonpathogenic microorganisms dried up in a culture medium specified in a number: Bifidobacterium bacteria and/or Lactobacillus bacteria, and/or species-specific virulent bacteriophages, and/or species-specific bacteriophages with induced virulence or their combinations with the composition containing target additives able to form a stable foam structure, is characterised by porous structure and fragility, has a relative disintegration shrinkage at least 10 %, equivalent pore diameter 10-110 mcm at particle size no more than 100 mcm and a resting angle less than 50° in the following proportions in 1.0 g of the composition: Bifidobacterium bacteria 106-1010 CFU and/or Lactobacillus bacteria 106-1010 CFU, and/or species-specific virulent bacteriophages of Appelman's lytic activity at least 10-4 with respect to test strains and bacterial isolates recovered from a human body, and/or species-specific bacteriophages of induced virulence of Appelman's lytic activity at least 10-4 with respect to test strains and bacterial isolates recovered from a human body, target additives - the rest.EFFECT: invention provides maximally achieved isotropic filling of the set volume of drug containers that provides accurate dosage of nonpathogenic microorganisms.7 cl, 9 exГруппа изобретений относится к фармацевтической промышленности и к медицине и может быть использована в производстве и использовании медицинских иммунобиологических препаратов, содержащих непатогенные микроорганизмы. Композиции (варианты) представляют собой порошок, включающий субстанции, содержащие непатогенные микроорганизмы, высушенные в среде культивирования, выбранные из ряда: бактерии рода Bifidobacterium и/или бактерии рода
